Vanguard Group Inc Glycomimetics Inc Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Shares
13 transactions
Others Institutions Holding GLYC
# of Institutions
5Shares Held
750KCall Options Held
0Put Options Held
0About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $823M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...